STRATEGIC USE OF PHARMACOECONOMIC RESEARCH IN EARLY DRUG DEVELOPMENT AND GLOBAL PRICING

被引:24
作者
CLEMENS, K
GARRISON, LP
JONES, A
MACDONALD, F
机构
[1] Pharmacoeconomic Research Department, Syntex Development Research, Division of Syntex (USA) Inc., Palo Alto, California, 94304, 3401 Hillview Avenue
[2] Pharmacoeconomic Research Department, Syntex Development Research - Europe, Maidenhead, Berkshire
关键词
D O I
10.2165/00019053-199304050-00002
中图分类号
F [经济];
学科分类号
02 ;
摘要
[No abstract available]
引用
收藏
页码:315 / 322
页数:8
相关论文
共 18 条
[1]  
Bootman J.L., Larson L.N., McGhan W.F., Townsend R.J., Pharmacoeconomic research and clinical trials: concepts and issues, Drug Intelligence and Clinical Pharmacy, 23, pp. 693-697, (1989)
[2]  
Burstall M.L., Europe aftcr 1992: implications for pharmaceuticals, Health Affairs, 10, 3, pp. 151-171, (1991)
[3]  
Chrischillcs E.A., The contributions of epidemiology to pharmacoeconomic research, Drug Information Journal, 26, pp. 219-229, (1992)
[4]  
Detsky A., Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada, PharmacoEconomics, 3, pp. 354-361, (1993)
[5]  
Di Masi J.A., Hansen R.W., Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry, Journal of Health Economics, 10, pp. 235-238, (1991)
[6]  
Drummond M., Cost-of-illness studies: a major headache?, PharmacoEconomics, 2, pp. 1-4, (1992)
[7]  
Drummond M.F., Teeling-Smilh G., Wells N., Economic evluation in the development of medicincs, (1988)
[8]  
Eddy D.M., What’s going on in Oregon?, Journal of the American Medical Associalion, 266, 3, pp. 417-420, (1991)
[9]  
Eddy J.M., Oregon’s methods: did cosl-effectiveness analysis fail?, Journal of the American Medical Association, 266, 15, pp. 2135-2141, (1991)
[10]  
Fulda T.R., Hass S.L., Medicaid drug utilisation review under OBRA 1990: current issues and future directions, PharmacoEconomics, 2, pp. 363-370, (1993)